Literature DB >> 17525289

Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells.

Emma L Davenport1, Hannah E Moore, Alan S Dunlop, Swee Y Sharp, Paul Workman, Gareth J Morgan, Faith E Davies.   

Abstract

Plasma cells producing high levels of paraprotein are dependent on the unfolded protein response (UPR) and chaperone proteins to ensure correct protein folding and cell survival. We hypothesized that disrupting client-chaperone interactions using heat shock protein 90 (Hsp90) inhibitors would result in an inability to handle immunoglobulin production with the induction of the UPR and myeloma cell death. To study this, myeloma cells were treated with Hsp90 inhibitors as well as known endoplasmic reticulum stress inducers and proteasome inhibitors. Treatment with thapsigargin and tunicamycin led to the activation of all 3 branches of the UPR, with early splicing of XBP1 indicative of IRE1 activation, upregulation of CHOP consistent with ER resident kinase (PERK) activation, and activating transcription factor 6 (ATF6) splicing. 17-AAG and radicicol also induced splicing of XBP1, with the induction of CHOP and activation of ATF6, whereas bortezomib resulted in the induction of CHOP and activation of ATF6 with minimal effects on XBP1. After treatment with all drugs, expression levels of the molecular chaperones BiP and GRP94 were increased. All drugs inhibited proliferation and induced cell death with activation of JNK and caspase cleavage. In conclusion, Hsp90 inhibitors induce myeloma cell death at least in part via endoplasmic reticulum stress and the UPR death pathway.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17525289     DOI: 10.1182/blood-2006-11-053728

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  100 in total

1.  Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.

Authors:  Loredana Santo; Teru Hideshima; Andrew L Kung; Jen-Chieh Tseng; David Tamang; Min Yang; Matthew Jarpe; John H van Duzer; Ralph Mazitschek; Walter C Ogier; Diana Cirstea; Scott Rodig; Homare Eda; Tyler Scullen; Miriam Canavese; James Bradner; Kenneth C Anderson; Simon S Jones; Noopur Raje
Journal:  Blood       Date:  2012-01-19       Impact factor: 22.113

2.  Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells.

Authors:  Rekha Rao; Srilatha Nalluri; Warren Fiskus; Andrew Savoie; Kathleen M Buckley; Kyungsoo Ha; Ramesh Balusu; Atul Joshi; Veena Coothankandaswamy; Jianguo Tao; Eduardo Sotomayor; Peter Atadja; Kapil N Bhalla
Journal:  Clin Cancer Res       Date:  2010-07-20       Impact factor: 12.531

3.  Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma.

Authors:  Chungyee Leung-Hagesteijn; Natalie Erdmann; Grace Cheung; Jonathan J Keats; A Keith Stewart; Donna E Reece; Kim Chan Chung; Rodger E Tiedemann
Journal:  Cancer Cell       Date:  2013-09-09       Impact factor: 31.743

4.  The novel autophagy inhibitor elaiophylin exerts antitumor activity against multiple myeloma with mutant TP53 in part through endoplasmic reticulum stress-induced apoptosis.

Authors:  Gaoxiang Wang; Pan Zhou; Xing Chen; Lei Zhao; Jiaqi Tan; Yang Yang; Yong Fang; Jianfeng Zhou
Journal:  Cancer Biol Ther       Date:  2017-07-18       Impact factor: 4.742

5.  Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma.

Authors:  Naoya Mimura; Mariateresa Fulciniti; Gullu Gorgun; Yu-Tzu Tai; Diana Cirstea; Loredana Santo; Yiguo Hu; Claire Fabre; Jiro Minami; Hiroto Ohguchi; Tanyel Kiziltepe; Hiroshi Ikeda; Yutaka Kawano; Maureen French; Martina Blumenthal; Victor Tam; Nathalie L Kertesz; Uriel M Malyankar; Mark Hokenson; Tuan Pham; Qingping Zeng; John B Patterson; Paul G Richardson; Nikhil C Munshi; Kenneth C Anderson
Journal:  Blood       Date:  2012-04-26       Impact factor: 22.113

6.  Efficacy of the HSP70 inhibitor PET-16 in multiple myeloma.

Authors:  Charvann K Bailey; Anna Budina-Kolomets; Maureen E Murphy; Yulia Nefedova
Journal:  Cancer Biol Ther       Date:  2015-07-15       Impact factor: 4.742

Review 7.  Preclinical studies of novel targeted therapies.

Authors:  Teru Hideshima; Kenneth C Anderson
Journal:  Hematol Oncol Clin North Am       Date:  2007-12       Impact factor: 3.722

8.  Hsp90 regulates the phosphorylation and activity of serum- and glucocorticoid-regulated kinase-1.

Authors:  Larissa Belova; Deanna R Brickley; Betty Ky; Sanjay K Sharma; Suzanne D Conzen
Journal:  J Biol Chem       Date:  2008-05-02       Impact factor: 5.157

9.  Anti-malaria drug blocks proteotoxic stress response: anti-cancer implications.

Authors:  Nickolay Neznanov; Anton V Gorbachev; Lubov Neznanova; Andrei P Komarov; Katerina V Gurova; Alexander V Gasparian; Amiya K Banerjee; Alexandru Almasan; Robert L Fairchild; Andrei V Gudkov
Journal:  Cell Cycle       Date:  2009-12-25       Impact factor: 4.534

10.  Co-treatment with heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and vorinostat: a highly active combination against human mantle cell lymphoma (MCL) cells.

Authors:  Rekha Rao; Pearl Lee; Warren Fiskus; Yonghua Yang; Rajeshree Joshi; Yongchao Wang; Kate Buckley; Ramesh Balusu; Jianguang Chen; Sanjay Koul; Atul Joshi; Sunil Upadhyay; Jianguo Tao; Eduardo Sotomayor; Kapil N Bhalla
Journal:  Cancer Biol Ther       Date:  2009-07       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.